^
    Back
    Association details:
    Biomarker:IGF1R amplification
    Cancer:HER2 Positive Breast Cancer
    Drug Class:CDK4 inhibitor +
    CDK6 inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    SABCS 2020
    Title:

    Igf1r mediates cdk4/6 inhibitor (cdk4/6i) resistance in tumor samples and in cellular models

    Published date:
    11/17/2020
    Excerpt:
    "We identified seven patients with HR+ MBC and IGF1R amplifications via targeted sequencing of tumor biopsies. Five of these patients had exposure to CDK4/6i-based therapy in the metastatic setting. Three patients demonstrated intrinsic resistance to CDK4/6i treatment (with duration <6 months)..."